Breaking News: New Research Highlights Potential of Evenamide in Schizophrenia Treatment
milan, Italy – Febuary 29, 2024 – Newron Pharmaceuticals announced today promising results from a preclinical study published in the esteemed journal Neuropsychopharmacology, underlining the potential of Evenamide in the treatment of schizophrenia. The research, conducted at the University of Pittsburgh, demonstrates Evenamide’s ability to target the hippocampus, a key area affected by the pathology of schizophrenia.
The study reveals that Evenamide effectively alleviates positive, negative, and cognitive symptoms in a model of schizophrenia. Sannume, a crucial component of Evenamide, exhibits prolonged effects beyond drug elimination, suggesting a significant impact on neuronal plasticity. This innovative approach focuses on hippocampal hyperexcitability, a mechanism currently unaddressed by existing treatments, offering renewed hope for patients with treatment-resistant schizophrenia.
These findings build upon the encouraging results from prior Phase II and Phase III clinical trials, indicating evenamide’s potential for ample
